Skip to main content Accessibility help
×
Hostname: page-component-7479d7b7d-767nl Total loading time: 0 Render date: 2024-07-11T00:08:27.394Z Has data issue: false hasContentIssue false

Chapter 26 - Cystic Fibrosis Liver Disease in Children

from Section IV - Metabolic Liver Disease

Published online by Cambridge University Press:  19 January 2021

Frederick J. Suchy
Affiliation:
University of Colorado, Children’s Hospital Colorado, Aurora
Ronald J. Sokol
Affiliation:
University of Colorado, Children’s Hospital Colorado, Aurora
William F. Balistreri
Affiliation:
Cincinnati Children’s Hospital Medical Center, Cincinnati
Jorge A. Bezerra
Affiliation:
Cincinnati Children’s Hospital Medical Center, Cincinnati
Cara L. Mack
Affiliation:
University of Colorado, Children’s Hospital Colorado, Aurora
Benjamin L. Shneider
Affiliation:
Texas Children’s Hospital, Houston
Get access

Summary

Cystic fibrosis (CF) is a genetic disorder characterized by epithelial electrolyte transport abnormalities, elevated sweat Cl concentrations, pancreatic insufficiency, and chronic lung disease in most patients. It is the most common potentially fatal genetic disorder in the Caucasian population, affecting 1 in 2,400–3,500 live births [1, 2]. It is an autosomal recessive disorder caused by a mutation in the gene CFTR encoding the cystic fibrosis transmembrane conductance regulator (CFTR), a membrane channel protein. The clinical significance of hepatobiliary disease in CF has not been well characterized primarily because of two factors: (1) pulmonary involvement leads to early mortality in a majority of patients, and (2) the clinical identification of CF-associated liver disease has been difficult because, although it is progressive, liver involvement is often asymptomatic until the appearance of end-stage complications. Recently, with improved pulmonary treatments, median life expectancy now exceeds 40 years and CF-associated hepatobiliary disease is recognized and characterized more comprehensively. Liver disease is now the third major cause of death in CF (after pulmonary disease and complications of lung transplant). In recent years, advances in our understanding of the function of CFTR in bile duct epithelia have provided a stronger scientific basis for the pathogenesis of the disease, leading to insights concerning potentially novel therapeutic approaches.

Type
Chapter
Information
Publisher: Cambridge University Press
Print publication year: 2021

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Kosorok, MR, Wei, WH, Farrell, PM. The incidence of cystic fibrosis. Stat Med 1996;15:449–62.3.0.CO;2-X>CrossRefGoogle ScholarPubMed
Dodge, JA, Morison, S, Lewis, PA, et al. Incidence, population, and survival of cystic fibrosis in the UK, 1968–95. UK Cystic Fibrosis Survey Management Committee. Arch Dis Child 1997;77:493–6.Google ScholarPubMed
Anderson, D. Cystic fibrosis of the pancreas and its relation to celiac disease: a clinical and pathological study. Am J Dis Child 1938;56(2):344–99.Google Scholar
Quinton, PM. Chloride impermeability in cystic fibrosis. Nature 1983;301 (5899):421–2.Google Scholar
Riordan, JR, Rommens, JM, Kerem, B, et al. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 1989;245 (4922):1066–73.CrossRefGoogle ScholarPubMed
Schwiebert, EM, Benos, DJ, Egan, ME, Stutts, MJ, Guggino, WB. CFTR is a conductance regulator as well as a chloride channel. Physiol Rev 1999;79(1 Suppl):S145S166.CrossRefGoogle ScholarPubMed
Gabriel, SE, Clarke, LL, Boucher, RC, Stutts, MJ. CFT R and outward rectifying chloride channels are distinct proteins with a regulatory relationship. Nature 1993;363(6426):263–8.Google Scholar
Dutta, AK, Khimji, AK, Kresge, C, et al. Identification and functional characterization of TMEM16A, a Ca2+-activated Cl channel activated by extracellular nucleotides in biliary epithelium. J Biol Chem 2011;286: 766–76.Google Scholar
Li, Q, Kresge, C, Bugde, A, Lamphere, M, Park, JY, Feranchak, AP. Regulation of mechanosensitive biliary epithelial transport by the epithelial Na(+) channel. Hepatology 2016;63(2):538–49. doi:10.1002/hep.28301CrossRefGoogle ScholarPubMed
Braunstein, GM, Roman, RM, Clancy, JP, et al. Cystic fibrosis transmembrane conductance regulator facilitates ATP release by stimulating a separate ATP release channel for autocrine control of cell volume regulation. J Biol Chem 2001;276:6621–30.Google Scholar
Fouassier, L, Duan, CY, Feranchak, AP, et al. Ezrin-radixin-moesin-binding phosphoprotein 50 is expressed at the apical membrane of rat liver epithelia. Hepatology 2001;33:166–76.Google Scholar
Cohn, JA, Strong, TV, Picciotto, MR, et al. Localization of the cystic fibrosis transmembrane conductance regulator in human bile duct epithelial cells. Gastroenterology 1993;105:1857–64.CrossRefGoogle ScholarPubMed
Fitz, JG, Basavappa, S, McGill, J, Melhus, O, Cohn, JA. Regulation of membrane chloride currents in rat bile duct epithelial cells. J Clin Invest 1993;91:319–28.Google Scholar
Fitz, JG. (1996). Cellular mechanisms of bile secretion. In Zakim, D, Boyer, TD (Eds.), Hepatology, 3rd edn (pp. 362–76). Philadelphia, PA: Saunders.Google Scholar
Dutta, AK, Khimji, AK, Sathe, M, et al. Identification and functional characterization of the intermediate-conductance Ca(2+)-activated K(+) channel (IK-1) in biliary epithelium. Am J Physiol Gastrointest Liver Physiol 2009;297:G1009G1018.Google Scholar
Feranchak, AP, Sokol, RJ. Cholangiocyte biology and cystic fibrosis liver disease. Sem Liv Disease 2001;21:471–88.Google Scholar
Clarke, LL, Grubb, BR, Yankaskas, JR, et al. Relationship of a non-cystic fibrosis transmembrane conductance regulator-mediated chloride conductance to organ-level disease in Cftr(–/–) mice. Proc Natl Acad Sci USA 1994;91:479–83.Google Scholar
Dutta, AK, Khimji, AK, Kresge, C, Bugde, A, Dougherty, M, Esser, V, Ueno, Y, Glaser, SS, Alpini, G, Rockey, DC, Feranchak, AP. Identification and functional characterization of TMEM16A, a Ca2+-activated Cl channel activated by extracellular nucleotides, in biliary epithelium. J Biol Chem. 2011 Jan 7;286(1):766–76. doi: 10.1074/jbc.M110.164970. Epub 2010 Nov 1. https://pubmed.ncbi.nlm.nih.gov/21041307/Google Scholar
Feranchak, AP, Fitz, JG. Adenosine triphosphate release and purinergic regulation of cholangiocyte transport. Semin Liver Dis 2002;22:251–62.Google Scholar
Dutta, AK, Woo, K, Doctor, RB, Fitz, JG, Feranchak, AP. Extracellular nucleotides stimulate Cl currents in biliary epithelia through receptor-mediated IP3 and Ca2+ release. Am J Physiol Gastrointest Liver Physiol 2008;295:G1004G1015.Google Scholar
Woo, K, Dutta, AK, Patel, V, Kresge, C, Feranchak, AP. Fluid flow induces mechanosensitive ATP release, calcium signalling and Cl transport in biliary epithelial cells through a PKCzeta-dependent pathway. J Physiol 2008;586(Pt 11):2779–98.CrossRefGoogle ScholarPubMed
Fiorotto, R, Scirpo, R, Trauner, M, et al. Loss of CFTR affects biliary epithelium innate immunity and causes TLR4–NF-κB: mediated inflammatory response in mice. Gastroenterology 2011;141(4):1498–508.e5. doi:10.1053/j.gastro.2011.06.052CrossRefGoogle ScholarPubMed
Fiorotto, R, Villani, A, Kourtidis, A, et al. The cystic fibrosis transmembrane conductance regulator controls biliary epithelial inflammation and permeability by regulating Src tyrosine kinase activity. Hepatology 2016;64(6):2118–34. doi:10.1002/hep.28817Google Scholar
Gabriel, SE, Brigman, KN, Koller, BH, Boucher, RC, Stutts, MJ. Cystic fibrosis heterozygote resistance to cholera toxin in the cystic fibrosis mouse model. Science 1994;266(5182):107–9.CrossRefGoogle ScholarPubMed
Quinton, PM. Role of epithelial HCO3 transport in mucin secretion: lessons from cystic fibrosis. Am J Physiol Cell Physiol 2010;299:C1222C1233.Google Scholar
Debray, D, El Mourabit, H, Merabtene, F, et al. Diet-induced dysbiosis and genetic background synergize with cystic fibrosis transmembrane conductance regulator deficiency to promote cholangiopathy in mice. Hepatol Commun 2018;2(12):1533–49. doi:10.1002/hep4.1266CrossRefGoogle ScholarPubMed
Scanlan, PD, Buckling, A, Kong, W, Wild, Y, Lynch, S V, Harrison, F. Gut dysbiosis in cystic fibrosis. J Cyst Fibros 2012;11(5):454–5. doi:10.1016/j.jcf.2012.03.007Google Scholar
Parisi, GF, Papale, M, Rotolo, N, et al. Severe disease in cystic fibrosis and fecal calprotectin levels. Immunobiology 2017;222(3):582–6. doi:10.1016/j.imbio.2016.11.005CrossRefGoogle ScholarPubMed
Blanco, PG, Zaman, MM, Junaidi, O, et al. Induction of colitis in cftr −/− mice results in bile duct injury. Am J Physiol Liver Physiol. 2004;287(2):G491G496. doi:10.1152/ajpgi.00452.2003Google Scholar
Flass, T, Tong, S, Frank, DN, et al. Intestinal lesions are associated with altered intestinal microbiome and are more frequent in children and young adults with cystic fibrosis and cirrhosis. PLoS One. 2015;10(2):e0116967. doi:10.1371/journal.pone.0116967Google Scholar
Smith, JL, Lewindon, PJ, Hoskins, AC, et al. Endogenous ursodeoxycholic acid and cholic acid in liver disease due to cystic fibrosis. Hepatology 2004;39:1673–82.Google Scholar
Brazova, J, Sediva, A, Pospisilova, D, et al. Differential cytokine profile in children with cystic fibrosis. Clin Immunol. 2005;115(2):210–15. doi:10.1016/j.clim.2005.01.013Google Scholar
Jacquot, J, Tabary, O, Le Rouzic, P, Clement, A. Airway epithelial cell inflammatory signalling in cystic fibrosis. Int J Biochem Cell Biol. 2008;40(9):1703–15. doi:10.1016/j.biocel.2008.02.002Google Scholar
Paats, MS, Bergen, IM, Bakker, M, et al. Cytokines in nasal lavages and plasma and their correlation with clinical parameters in cystic fibrosis. J Cyst Fibros. 2013;12(6):623–9. doi:10.1016/j.jcf.2013.05.002CrossRefGoogle ScholarPubMed
McGill, JM, Yen, MS, Cummings, OW, et al. Interleukin-5 inhibition of biliary cell chloride currents and bile flow. Am J Physiol Gastrointest Liver Physiol 2001;280(4):G738–45. doi:10.1152/ajpgi.2001.280.4.G738Google Scholar
Spirlì, C, Fabris, L, Duner, E, et al. Cytokine-stimulated nitric oxide production inhibits adenylyl cyclase and cAMP-dependent secretion in cholangiocytes. Gastroenterology 2003;124(3):737–53. doi:10.1053/gast.2003.50100Google Scholar
Spirlì, C, Nathanson, MH, Fiorotto, R, et al. Proinflammatory cytokines inhibit secretion in rat bile duct epithelium. Gastroenterology 2001;121(1):156–69. doi:10.1053/gast.2001.25516Google Scholar
Sun, H, Harris, WT, Kortyka, S, et al. Tgf-beta downregulation of distinct chloride channels in cystic fibrosis-affected epithelia. PLoS One. 2014;9(9):e106842. doi:10.1371/journal.pone.0106842Google Scholar
Lewindon, PJ, Pereira, TN, Hoskins, AC, et al. The role of hepatic stellate cells and transforming growth factor-beta(1) in cystic fibrosis liver disease. Am J Pathol 2002;160:1705–15.Google Scholar
Fiorotto, R, Amenduni, M, Mariotti, V, et al. Animal models for cystic fibrosis liver disease. Biochim Biophys Acta – Mol Basis Dis 2019;1865(5):965–9. doi:10.1016/j.bbadis.2018.07.026Google Scholar
Bartlett, JR, Friedman, KJ, Ling, SC, et al. Genetic modifiers of liver disease in cystic fibrosis. JAMA 2009;302:1076–83.Google Scholar
Duthie, A, Doherty, DG, Donaldson, PT, et al. The major histocompatibility complex influences the development of chronic liver disease in male children and young adults with cystic fibrosis. J Hepatol 1995;23:532–7.Google Scholar
Cystic Fibrosis Foundation (CFF). 2017 Patient Registry: Annual Data Report. Cyst Fibros Found Patient Regist. 2017:92.Google Scholar
Vawter, GF, Shwachman, H. Cystic fibrosis in adults: an autopsy study. Pathol Annu 1979;14:357–82.Google Scholar
Debray, D, Kelly, D, Houwen, R, Strandvik, B, Colombo, C. Best practice guidance for the diagnosis and management of cystic fibrosis-associated liver disease. J Cyst Fibros 2011;10:S29S36.CrossRefGoogle ScholarPubMed
Boëlle, P, Debray, D, Guillot, L, et al. Cystic fibrosis liver disease: outcomes and risk factors in a large cohort of French patients. Hepatology 2019;69(4):1648–56. doi:http://dx.doi.org/10.1002/hep.30148Google Scholar
Koh, C, Sakiani, S, Surana, P, et al. Adult-onset cystic fibrosis liver disease: diagnosis and characterization of an underappreciated entity. Hepatology 2017;66(2):591601. doi:https://dx.doi.org/10.1002/hep.29217Google Scholar
Colombo, C, Apostolo, MG, Ferrari, M, et al. Analysis of risk factors for the development of liver disease associated with cystic fibrosis. J Pediatr 1994;124:393–9.Google Scholar
Sokol, RJ, Durie, PR. Recommendations for management of liver and biliary tract disease in cystic fibrosis. Cystic Fibrosis Foundation Hepatobiliary Disease Consensus Group. J Pediatr Gastroenterol Nutr 1999;28(Suppl1):S1S13.Google Scholar
Flass, T, Narkewicz, MR. Cirrhosis and other liver disease in cystic fibrosis. J Cyst Fibros. 2013;12(2):116–24. doi:https://dx.doi.org/10.1016/j.jcf.2012.11.010Google Scholar
Sokol, RJ, Carroll, NM, Narkewicz, MR, et al. Liver blood tests during the first decade of life in children with cystic fibrosis identified by newborn screening. Pediatr Pulm 1994;10:275.Google Scholar
Woodruff, SA, Sontag, MK, Accurso, FJ, Sokol, RJ, Narkewicz, MR. Prevalence of elevated liver enzymes in children with cystic fibrosis diagnosed by newborn screen. J Cyst Fibros 2017;16(1):139–45. doi:https://dx.doi.org/10.1016/j.jcf.2016.08.002Google Scholar
Loverdos, I, Gonska, T, Ling, SC. Platelet count enables early diagnosis of cystic fibrosis liver disease (Conference Workshop WS17.3). J Cyst Fibros. 2016;15:S28.Google Scholar
Patriquin, H, Lenaerts, C, Smith, L, et al. Liver disease in children with cystic fibrosis: US-biochemical comparison in 195 patients. Radiology 1999;211: 229–32.Google Scholar
Lenaerts, C, Lapierre, C, Patriquin, H, et al. Surveillance for cystic fibrosis- associated hepatobiliary disease: early ultrasound changes and predisposing factors. J Pediatr 2003;143:343–50.Google Scholar
Narkewicz, MR. Cystic fibrosis liver disease: what is it and what happens as a result. Pediatr Pulmonol 2018;53(Supplement2):81–2. doi:http://dx.doi.org/10.1002/ppul.24151Google Scholar
Ling, SC, Ye, W, Leung, DH, et al. Liver ultrasound patterns in children with cystic fibrosis correlate with non-invasive tests of liver disease. J Pediatr Gastroenterol Nutr 2019;69:351. doi:10.1097/mpg.0000000000002413Google Scholar
Ling, SC. The use of serum biomarkers and imaging in the diagnosis and prediction of outcomes in CF liver disease. Pediatr Pulmonol 2018;53(Supplement2):8586. doi:http://dx.doi.org/10.1002/ppul.24151Google Scholar
Sathe, MN, Freeman, AJ. Gastrointestinal, pancreatic, and hepatobiliary manifestations of cystic fibrosis. Pediatr Clin North Am 2016;63(4):679–98. doi:https://dx.doi.org/10.1016/j.pcl.2016.04.008Google Scholar
Aqul, A, Jonas, MM, Harney, S, et al. Correlation of transient elastography with severity of cystic fibrosis-related liver disease. J Pediatr Gastroenterol Nutr 2017;64(4):505–11. doi:https://dx.doi.org/10.1097/MPG.0000000000001448Google Scholar
Gominon, A-L, Frison, E, Hiriart, J-B, et al. Assessment of liver disease progression in cystic fibrosis using transient elastography. J Pediatr Gastroenterol Nutr 2018;66(3):455–60. doi:https://dx.doi.org/10.1097/MPG.0000000000001822Google Scholar
Lewindon, PJ, Puertolas-Lopez, MV. , Ramm, LE, et al. Accuracy of transient elastography data combined with APRI in detection and staging of liver disease in pediatric patients with cystic fibrosis. Clin Gastroenterol Hepatol 2019. doi:10.1016/j.cgh.2019.03.015Google Scholar
Leung, DH, Khan, M, Minard, CG, et al. Aspartate aminotransferase to platelet ratio and fibrosis-4 as biomarkers in biopsy-validated pediatric cystic fibrosis liver disease. Hepatology 2015;62(5):1576–83. doi:https://dx.doi.org/10.1002/hep.28016Google Scholar
Ling, SC, Ye, W, Leung, DH, et al. Baseline liver echotexture in children with cystic fibrosis predicts changes over time in non-invasive biomarkers of fibrosis and portal hypertension. J Pediatr Gastroenterol Nutr 2017;65(Supplement 1):77A-78A. doi:http://dx.doi.org/10.1097/MPG.0000000000001805Google Scholar
Cook, NL, Pereira, TN, Lewindon, PJ, Shepherd, RW, Ramm, GA. Circulating microRNAs as noninvasive diagnostic biomarkers of liver disease in children with cystic fibrosis. J Pediatr Gastroenterol Nutr 2015;60(2):247–54. doi:10.1097/MPG.0000000000000600Google Scholar
Heuman, DM. Hepatoprotective properties of ursodeoxycholic acid. Gastroenterology 1993;104:1865–70.CrossRefGoogle ScholarPubMed
Shimokura, GH, McGill, JM, Schlenker, T, Fitz, JG. Ursodeoxycholate increases cytosolic calcium concentration and activates Cl currents in a biliary cell line. Gastroenterology 1995;109:965–72.Google Scholar
Colombo, C, Crosignani, A, Assaisso, M, et al. Ursodeoxycholic acid therapy in cystic fibrosis-associated liver disease: a dose-response study. Hepatology 1992;16:924–30.Google Scholar
Lindblad, A, Glaumann, H, Strandvik, B. A two-year prospective study of the effect of ursodeoxycholic acid on urinary bile acid excretion and liver morphology in cystic fibrosis-associated liver disease. Hepatology 1998;27:166–74.Google Scholar
Nousia-Arvanitakis, S, Fotoulaki, M, Economou, H, Xefteri, M, Galli-Tsinopoulou, A. Long-term prospective study of the effect of ursodeoxycholic acid on cystic fibrosis-related liver disease. J Clin Gastroenterol 2001;32:324–8.Google Scholar
Lindor, KD, Kowdley, KV, Luketic, VA, et al. High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. Hepatology 2009;50:808–14.Google Scholar
Gong, Y, Huang, ZB, Christensen, E, Gluud, C. Ursodeoxycholic acid for primary biliary cirrhosis. Cochrane Database Syst Rev 2008;8:CD000551.Google Scholar
Ooi, CY, Nightingale, S, Durie, PR, Freedman, SD. Ursodeoxycholic acid in cystic fibrosis-associated liver disease. J Cyst Fibros 2012;11:72–3.CrossRefGoogle ScholarPubMed
Cheng, K, Ashby, D, Smyth, RL. Ursodeoxycholic acid for cystic fibrosis-related liver disease. Cochrane Database Syst Rev 2017;9:CD000222. doi:https://dx.doi.org/10.1002/14651858.CD000222.pub4Google Scholar
Ye, W, Narkewicz, MR, Leung, DH, et al. Variceal hemorrhage and adverse liver outcomes in patients with cystic fibrosis cirrhosis. J Pediatr Gastroenterol Nutr 2018;66(1):122–7. doi:https://dx.doi.org/10.1097/MPG.0000000000001728CrossRefGoogle ScholarPubMed
Lemoine, C, Lokar, J, McColley, SA, Alonso, EM, Superina, R. Cystic fibrosis and portal hypertension: Distal splenorenal shunt can prevent the need for future liver transplant. J Pediatr Surg 2019. doi:http://dx.doi.org/10.1016/j.jpedsurg.2019.01.035Google Scholar
Molleston, J. Medical and surgical management of complication of portal hypertension in CF. Pediatr Pulmonol 2018;53:S84–5.Google Scholar
Gridelli, B. Liver: benefit of liver transplantation in patients with cystic fibrosis. Nat Rev Gastroenterol Hepatol 2011;8:187–8.Google Scholar
Yang, Y, Raper, SE, Cohn, JA, Engelhardt, JF, Wilson, JM. An approach for treating the hepatobiliary disease of cystic fibrosis by somatic gene transfer. Proc Natl Acad Sci USA 1993;90:4601–5.CrossRefGoogle ScholarPubMed
Becq, F, Mall, MA, Sheppard, DN, Conese, M, Zegarra-Moran, O. Pharmacological therapy for cystic fibrosis: from bench to bedside.J Cyst Fibros 2011;10(Suppl2):S129S145.Google Scholar
Hayes, D, Warren, PS, McCoy, KS, Sheikh, SI. Improvement of hepatic steatosis in cystic fibrosis with ivacaftor therapy. J Pediatr Gastroenterol Nutr 2015;60(5):578–9. doi:10.1097/MPG.0000000000000765Google Scholar
Chaudary, N. Triplet CFTR modulators: future prospects for treatment of cystic fibrosis. Ther Clin Risk Manag 2018;14:2375–83. doi:10.2147/TCRM.S147164Google Scholar
Bodewes, FAJA, van der Wulp, MYM, Beharry, S, et al. Altered intestinal bile salt biotransformation in a cystic fibrosis (Cftr−/−) mouse model with hepato-biliary pathology. J Cyst Fibros 2015;14(4):440–6. doi:10.1016/j.jcf.2014.12.010Google Scholar
Van de Peppel, IP, Bodewes, FAJA, Verkade, HJ, Jonker, JW. Bile acid homeostasis in gastrointestinal and metabolic complications of cystic fibrosis. J Cyst Fibros. 2019;18(3):313–20. doi:10.1016/j.jcf.2018.08.009Google Scholar
Wiest, R, Albillos, A, Trauner, M, Bajaj, JS, Jalan, R. Targeting the gut-liver axis in liver disease. J Hepatol 2017;67(5):1084–103. doi:10.1016/j.jhep.2017.05.007Google Scholar

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×